A research project on a cannabis cancer cure is under investigation amid allegations over ethical approvals.

Web-based platform includes updated information about health effects of cannabis, searchable compilation of latest research.

New York’s cannabis market is poised for major growth in 2025, with sales expected to hit $1.5 billion and the number of legal marijuana shops more than doubling. Dan Ahrens, AdvisorShares Pure US Cannabis ETF portfolio manager, joins Market Domination to discuss how current political delays and market volatility have affected cannabis stock. "We keep expecting federal reform, we keep getting promised federal reform, and when we had this past election, these cannabis stocks took yet another hit because the investing public out there really thinks that the Republican Party is bad for cannabis," Ahrens explains. He notes the Democratic Party could have been good for cannabis but that "people in our space feel like we've just been gaslighted for the past four years by Democrats.” Ahrens still suggests 2025 could bring change, with cannabis potentially rescheduled as a Schedule III controlled substance, which would be a big positive for companies. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Josh Lynch

An audio summary of this article is available in the player below. Scroll to keep reading. Listen and subscribe to Womble Perspectives wherever you get your podcasts. This article was authored by Laura Kiser, Research Analyst.After three years and lots of back-and-forth, the FDA finally

New findings indicate cannabis contributes to severe cellular and genetic damage, raising cancer risks and potentially affecting future generations. Cannabis use has been linked to cellular damage that significantly increases the risk of developing highly cancerous tumors, according to a new stud